title: Prognostic Value of Metabolic and Volumetric Parameters of Preoperative FDG-PET/CT in Patients With Resectable Pancreatic Cancer.
abstract: In this study, we aimed to evaluate prognostic value of metabolic and volumetric parameters measured from F fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with resectable pancreatic cancer.Fifty-one patients with resectable pancreatic cancer who underwent FDG-PET/CT and curative operation were retrospectively enrolled. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were measured from FDG-PET/CT. Association between FDG-PET/CT and clinicopathologic parameters was evaluated. The prognostic values of the FDG-PET/CT and clinicopathologic parameters for recurrence-free survival (RFS) and overall survival (OS) were assessed by univariate and multivariate analyses.The 51 enrolled patients were followed up for a median of 21 months (mean ± SD: 23 ± 16 months, range: 1-78 months) with 33 (65%) recurrences and 30 (59%) deaths during the period. SUVmax, MTV, and TLG were associated with Tumor node metastasis (TNM) stage and presence of lymph node metastasis. MTV and TLG were associated with presence of lymphovascular invasion, whereas SUVmax was not. On the univariate analysis, SUVmax, MTV, and TLG were associated with RFS and OS. Also, lymph node metastasis and TNM stage were associated with OS on the univariate analysis. On multivariate analysis, MTV and TLG were independent prognostic factors for RFS and OS. SUVmax was an independent prognostic factor for OS, but not for RFS.Metabolic tumor volume and TLG were independently predictive of RFS and OS in resectable pancreatic cancer. SUVmax was an independent factor for OS, but not for RFS.
authors.affiliation: From the Department of Nuclear Medicine (H-JI, SO, GJC KWK, J-KC, DSL), Seoul National University College of Medicine; Department of Molecular Medicine and Biopharmaceutical Sciences (H-JI, EEK, DSL), Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy; Department of Surgery (WJ, J-YJ, S-WK), Seoul National University College of Medicine; Cancer Research Institute (WJ, J-YJ, S-WK, GJC, KWK, J-KC, DSL), Seoul National University College of Medicine, Seoul, Korea; and Department of Radiological Science, University of California at Irvine, CA (EEK).
authors.forename: Hyung-Jun
authors.initials: HJ
authors.lastname: Im
authors.forename: Suthet
authors.initials: S
authors.lastname: Oo
authors.forename: Woohyun
authors.initials: W
authors.lastname: Jung
authors.forename: Jin-Young
authors.initials: JY
authors.lastname: Jang
authors.forename: Sun-Whe
authors.initials: SW
authors.lastname: Kim
authors.forename: Gi Jeong
authors.initials: GJ
authors.lastname: Cheon
authors.forename: Keon Wook
authors.initials: KW
authors.lastname: Kang
authors.forename: June-Key
authors.initials: JK
authors.lastname: Chung
authors.forename: E Edmund
authors.initials: EE
authors.lastname: Kim
authors.forename: Dong Soo
authors.initials: DS
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism*; D006019:Glycolysis; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000209:etiology; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000601:surgery; D000072078:Positron Emission Tomography Computed Tomography / Q000379:methods*; D057234:Preoperative Period; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000378:metabolism*; D012189:Retrospective Studies; D047368:Tumor Burden
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18